These findings suggest that the identified genes, particularly CDC20, H2AX, H3C13, HK2, and ITGB4, may serve as potential therapeutic targets for overcoming drug resistance in cholangiocarcinoma. Here, ITGB4 is linked to cholangiocarcinoma.